Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 10 of 10 publications.

Bagnato F, Mordin M, Greene N, Mahida S, Higuchi K, Wingerden J. Evaluating association of chronic active lesions with disability in multiple sclerosis: a systematic literature review. Poster presented at the 10th Congress of the European Academy of Neurology; June 29, 2024. Helenski, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1).

Potashman MH, Rudell K, Abetz-Webb L, Suminski N, Gold A, Doma R, Jarodia K, Buckley C, Ridley M, Lerner J, Mather J, Millichap J, Berg AT, L'Italien G. Understanding lived experiences with KCNQ2-development and epileptic encephalopathy (KCNQ2-DEE) - parent interviews. Poster presented at the Congress of the European Academy of Neurology (EAN); June 29, 2024. Helsinki, Finland. [abstract] Eur J Neurol. 2024 Jun; 31(Suppl 1):363.

Serbin M, Mansfield C, Leach CA, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Do patients' experiences with side effects affect their preferences for adjunctive Parkinson's disease treatments? Poster presented at the 8th European Academy of Neurology Congress; June 25, 2022. Vienna, Austria. [abstract] Eur J Neurol. 2022 Jun; 29(Suppl 1):446.

Mangel A, Lothman K. Commentary: emergence of a new paradigm in understanding the cardiovascular system: pulse synchronized contractions. Cardiovasc Pharm Open Access. 2017;6(5):220. doi: 10.4172/2329-6607.1000220

Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264

Groenwold R, Uddin M, Roes K, de Boer A, Rivero-Ferrer E, Martin E, Gatto N, Klungel O. Instrumental variable analysis in randomized trials with non-compliance and observational pharmacoepidemiologic studies. OA Epidemiology. 2014 May 9;2(1):9.

Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.

Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.

Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.

Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.